N/A N=1,487 Smoker-to-Smoker (S2S) Peer Marketing and Messaging to Disseminate Tobacco Interventions
Smoking Cessation
Primary: Smoking Cessation — 89; 57; 88; 68 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Effects of Smoking State on Decision Making
Behavior
Primary: Effort Based Decision Making — 29.5; 18.3 high effort selections
N/A N=40 Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
Smoking Behaviors
Primary: Number of Puffs Taken (Video-scored Smoking Behavior Outcome 1) — 15.8; 16.7; 19.1; 19.6 puffs
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
Phase 2 N=38 Treating Smokers With Mental Illness
Smoking Cessation · Cigarette Smoking · Schizophrenia
Primary: 7-Day Point Prevalence Abstinence — 5; 3; 4; 5 Participants
Phase 4 N=93 Varenicline for Light Smokers
Smoking
Primary: Point Prevalence Smoking Outcome at 12 Weeks (End of Treatment) — 24; 7 participants — p=<0.001
N/A N=187 Effects Among Smokers Who Use and Do Not Use E-Cigarettes
Toxicant Exposure
Primary: Toxicant Exposure — 40; 97 pg/ml
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
N/A N=184 Brain Nicotine Receptor Density in Veteran Smokers
Positron Emission Tomography
Primary: PET Scan, Rating Scales — 7.1; 8.6; 7.9; 8.0 Vt/fp or mL/cm3
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=22 Comparative Abuse Liability Among African American and White Smokers
Tobacco Use Disorder
Primary: Nicotine Delivery — 14.13; 6.79; 9.15 ng/mL — p=0.002
N/A N=25 Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
Healthy Volunteers
Primary: Nicotine Cmax — 13.00; 12.97; 6.00; 6.87 ng/mL
N/A N=150 Methods Project 4: Clinical Trial
Smoker
Primary: Smoke-free Days — 14.5; 0; 0 days
Phase 3 N=31 Project Q Pilot: Smoking Cessation for Light Smokers
Tobacco Use Cessation
Primary: Number of Participants With Completion of at Least 2 Study Visits — 10; 7; 1 Participants
N/A N=1,100 Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers
Smoker
Primary: Quit Intentions — 1.90; 1.72; 1.89; 1.79 units on a scale
N/A N=3,125 Nonsmokers Helping Smokers Quit
Smoking Cessation
Primary: Number of Participants Reporting 30-day Abstinence — 203; 222; 135 Participants
N/A N=60 Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-Cigarettes
Tobacco Use
Primary: Combustible Cigarette Use — 3.79; 3.64 Number of cigarettes smoked per day
N/A N=199 Perceptions of Cigarette Smoking in Young Adults
Smoking, Cigarette
Primary: Subjective Response to Smoking Cigarettes From the Cigarette Evaluation Scale — 4.68; 4.50 score on a scale — p=>.05
N/A N=281 Oral Cell DNA Adducts in Smokers
Lung Cancer
Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL
N/A N=30 Quit or Switch: E-cigarette Study
Tobacco Use
Primary: Percentage of Participants Who Report Daily Use of E-cigarettes or NRT and no Cigarette Use
N/A N=60 Smoking Topography and Harm Exposure in Menthol Cigarettes
Cigarette Smoking Toxicity
Primary: Smoking Topography- Puff Volume — 518; 661; 650; 620 mL
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=3,070 Young Adult Smoker's Treatment Demand
Smoking Cessation
Primary: Program Enrollment — .05 proportion of click-throughs who enroll
N/A N=238 Very-Low Nicotine Cigarettes and Non-Daily Smokers
Smoking
Primary: Change in Cigarette Consumption — -1.6; -0.05 cigarettes per day — p=<0.001
N/A N=24 A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco Products Compared to Combustible Cigarettes
Healthy Volunteers
Primary: Nicotine Cmax — 10.500; 7.539; 8.191; 21.680 ng/mL
Phase 4 N=11 Varenicline Light Smoking Pilot
Smoking Cessation · Smoking Behaviors · Smoking
Primary: Change in Self-Reported Craving Level Via Lab-Based Cue Reactivity — 6.31; 4.2; 2.56; 2.4 score on a scale
N/A N=40 A Study to Evaluate Nicotine Uptake and Biomarkers in Smokers Using mybluTM Electronic Cigarettes
Healthy Volunteers
Primary: Maximum Nicotine Concentration in Blood — 3.6; 5.3; 4.0; 5.3 ng/mL
N/A N=30 Switching to Potential Reduced Exposure Products in Adult Smokers
Tobacco Use Disorder · Oral Nicotine Pouch Use · Smoking Behaviors
Primary: Number of Cigarettes Smoked Per Day (Log-transformed) — 2.0; 1.8 number of cigarettes smoked
N/A N=22 Assessment of Two New Electronic Cigarettes in Cigarette Smokers
Electronic Cigarettes
Primary: Change in Plasma Nicotine — 7.62; 10.65; 18.31; 7.19 ng/ml
N/A N=33 Impact of Switching to Non-Menthol Cigarettes Among Smokers
Tobacco Use
Primary: Total Number of Cigarettes Smoked — 2.2 cigarettes per day